112 related articles for article (PubMed ID: 30806669)
1. Determination of the Critical Concentration of Rifabutin for Susceptibility Testing Using the Proportion Method with Löwenstein-Jensen Medium against Mycobacterium Tuberculosis Isolates.
Dai G; Chen S; Dong L; Li YX; Huo F; Shang Y; Huang H
Lab Med; 2019 Jul; 50(3):292-297. PubMed ID: 30806669
[TBL] [Abstract][Full Text] [Related]
2. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the
Guo Y; Cao X; Yang J; Wu X; Liu Y; Wan B; Hu L; Wang H; Yu F
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33507146
[No Abstract] [Full Text] [Related]
3. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.
Berrada ZL; Lin SY; Rodwell TC; Nguyen D; Schecter GF; Pham L; Janda JM; Elmaraachli W; Catanzaro A; Desmond E
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):177-81. PubMed ID: 27036978
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan.
Chien HP; Yu MC; Ong TF; Lin TP; Luh KT
J Formos Med Assoc; 2000 May; 99(5):408-11. PubMed ID: 10870331
[TBL] [Abstract][Full Text] [Related]
5. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
[TBL] [Abstract][Full Text] [Related]
6. [Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains].
Gao L; Xiao HP; Hu ZY; Cui ZL; Lu JM; Shen XN
Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):333-5. PubMed ID: 22883990
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Cavusoglu C; Karaca-Derici Y; Bilgic A
Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
[TBL] [Abstract][Full Text] [Related]
8. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
Sirgel FA; Warren RM; Böttger EC; Klopper M; Victor TC; van Helden PD
PLoS One; 2013; 8(3):e59414. PubMed ID: 23527189
[TBL] [Abstract][Full Text] [Related]
9. Differential Impact of the
Yu MC; Hung CS; Huang CK; Wang CH; Liang YC; Lin JC
Microbiol Spectr; 2022 Aug; 10(4):e0075422. PubMed ID: 35924839
[TBL] [Abstract][Full Text] [Related]
10. Rifabutin Resistance Associated with Double Mutations in
Jing W; Pang Y; Zong Z; Wang J; Guo R; Huo F; Jiang G; Ma Y; Huang H; Chu N
Front Microbiol; 2017; 8():1768. PubMed ID: 28959248
[TBL] [Abstract][Full Text] [Related]
11. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
Rastogi N; Goh KS; Berchel M; Bryskier A
J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis.
Chen HY; Yu MC; Huang WL; Wu MH; Chang YL; Che CR; Jou R
J Clin Microbiol; 2012 Jun; 50(6):2085-8. PubMed ID: 22442316
[TBL] [Abstract][Full Text] [Related]
13. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia.
Sintchenko V; Chew WK; Jelfs PJ; Gilbert GL
Pathology; 1999 Aug; 31(3):257-60. PubMed ID: 10503273
[TBL] [Abstract][Full Text] [Related]
14. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
[TBL] [Abstract][Full Text] [Related]
15. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
[TBL] [Abstract][Full Text] [Related]
16. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.
Yoshida S; Suzuki K; Iwamoto T; Tsuyuguchi K; Tomita M; Okada M; Sakatani M
J Infect Chemother; 2010 Oct; 16(5):360-3. PubMed ID: 20354890
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
Schön T; Juréen P; Chryssanthou E; Giske CG; Kahlmeter G; Hoffner S; Angeby K
J Antimicrob Chemother; 2013 Sep; 68(9):2074-7. PubMed ID: 23633684
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different methods of assessing in vitro resistance of Mycobacterium tuberculosis to rifampicin.
Paramasivan CN; Rahman F; Nalini S; Dakshayani G; Venkataraman P
Indian J Med Res; 2001 Dec; 114():187-91. PubMed ID: 12040761
[TBL] [Abstract][Full Text] [Related]
19. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
20. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis.
García AB; Palacios JJ; Ruiz MJ; Barluenga J; Aznar F; Cabal MP; García JM; Díaz N
Antimicrob Agents Chemother; 2010 Dec; 54(12):5363-5. PubMed ID: 20855731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
